HBIO · Harvard Bioscience, Inc.

Summary

Harvard Bioscience, Inc. held a Special Meeting of Stockholders on March 6, 2026, where shareholders approved a Reverse Stock Split Proposal. The Board approved a 1-for-10 reverse stock split effective March 13, 2026 at 4:30 p.m. ET, reducing outstanding Common Stock from approximately 44,179,894 to 4,471,989 shares while maintaining 80,000,000 authorized shares.

Key takeaways

• Special Meeting quorum: 27,715,066 shares (61.97% of outstanding Common Stock)
• Reverse Stock Split Proposal approved: 27,004,721 FOR, 677,700 AGAINST, 32,645 ABSTAIN
• Final 1-for-10 reverse stock split ratio approved by Board
• Effective Time: March 13, 2026 at 4:30 p.m. ET
• Post-split trading begins March 16, 2026 on Nasdaq under HBIO with new CUSIP 416906204
• No fractional shares; cash payments via aggregated sale by transfer agent